Tags

Type your tag names separated by a space and hit enter

[Value of Clodronate in the treatment of bone metastasis].
Bull Cancer. 1991; 78(8):737-41.BC

Abstract

The intravenous administration of Clodronate, a strong inhibitor of osteoclastic activity provides a safe and very effective treatment of hypercalcemia whether secondary to bone metastasis or due to paraneoplastic syndrome. Its action is fast, exclusively osseous and lasts up to 7 days. The response is incomplete when increased renal absorption is the predominant mechanism of hypercalcemia. The data published by Elomaa et al on osteolytic metastases in breast cancer patients show a significant improvement with regard to pain reduction, prevention of fractures as well as hypercalcemia. The results obtained using a 1-yr oral treatment need further confirmation.

Authors+Show Affiliations

Service de médecine oncologique, Institut Curie, Paris, France.No affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

fre

PubMed ID

1834287

Citation

Pouillart, P, and P Beuzeboc. "[Value of Clodronate in the Treatment of Bone Metastasis]." Bulletin Du Cancer, vol. 78, no. 8, 1991, pp. 737-41.
Pouillart P, Beuzeboc P. [Value of Clodronate in the treatment of bone metastasis]. Bull Cancer. 1991;78(8):737-41.
Pouillart, P., & Beuzeboc, P. (1991). [Value of Clodronate in the treatment of bone metastasis]. Bulletin Du Cancer, 78(8), 737-41.
Pouillart P, Beuzeboc P. [Value of Clodronate in the Treatment of Bone Metastasis]. Bull Cancer. 1991;78(8):737-41. PubMed PMID: 1834287.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Value of Clodronate in the treatment of bone metastasis]. AU - Pouillart,P, AU - Beuzeboc,P, PY - 1991/1/1/pubmed PY - 1991/1/1/medline PY - 1991/1/1/entrez SP - 737 EP - 41 JF - Bulletin du cancer JO - Bull Cancer VL - 78 IS - 8 N2 - The intravenous administration of Clodronate, a strong inhibitor of osteoclastic activity provides a safe and very effective treatment of hypercalcemia whether secondary to bone metastasis or due to paraneoplastic syndrome. Its action is fast, exclusively osseous and lasts up to 7 days. The response is incomplete when increased renal absorption is the predominant mechanism of hypercalcemia. The data published by Elomaa et al on osteolytic metastases in breast cancer patients show a significant improvement with regard to pain reduction, prevention of fractures as well as hypercalcemia. The results obtained using a 1-yr oral treatment need further confirmation. SN - 0007-4551 UR - https://www.unboundmedicine.com/medline/citation/1834287/[Value_of_Clodronate_in_the_treatment_of_bone_metastasis]_ L2 - https://medlineplus.gov/bonecancer.html DB - PRIME DP - Unbound Medicine ER -